Biotronik, a manufacturer of cardiovascular medical technology, has introduced its Ilesto DX system, which offers the established benefits of the DX System in a thinner and smaller device.
This launch follows the approval from the US Food and Drug Administration (FDA) for the company’s Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices).
Ilesto DX allows for a 15% size reduction and 29% fewer components than DX System, while offering same longevity and clinical features.
The DX System is reportedly the first defibrillator system to provide full atrial diagnostic information with just one specialized defibrillator lead.
Biotronik marketing and communications vice president Rex Richmond noted through advanced design and the use of robotic manufacturing, the company has developed a highly automated production process for the electronic module.
"The Ilesto platform is the latest example of BIOTRONIK’s guiding principle of engineering excellence into all of our products. This commitment underscores BIOTRONIK’s 50 year history as a medical technology leader," Richmond added.
The DX System is being considered as a solution to the limited capabilities of single chamber or the additional complications associated with dual chamber devices.